#EULAR2024 POS0326 Multicentre cohort in Italy (N=67) showed Benralizumab and Mepolizumab 300mg (EGPA dose) exhibited a

Social Author Image
https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg
Tweet Author
Yuz6Yusof
Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
#EULAR2024 POS0326 Multicentre cohort in Italy (N=67) showed Benralizumab and Mepolizumab 300mg (EGPA dose) exhibited a significant steroid-sparing effect, with MEPO300 demonstrating superior drug survival. MEPO100 (eosinophilic asthma dose) was numerically inferior @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.